ArticleArchives of gynecology and obstetrics2026
Association between preconception serum homocysteine levels and early pregnancy loss in women with recurrent pregnancy loss.
Article in Archives of gynecology and obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundElevated homocysteine (HCY) levels have been implicated in early pregnancy loss (EPL) but evidence remains inconclusive. The aim of this study was to investigate the association between preconception serum HCY levels and EPL in women who have experienced recurrent pregnancy loss (RPL).
methodsUsing data from a prospective dynamic pregnancy loss cohort established by our group, we screened 812 eligible patients with RPL, collected their medical records, and followed them for subsequent pregnancy outcomes. Multivariable logistic regression was used to assess the relationship between preconception serum HCY levels and the risk of subsequent EPL. Generalized additive models were also used to examine nonlinear associations between serum HCY levels and EPL. Subgroup analyses were further performed according to age, body mass index (BMI), and the number of previous pregnancy losses.
resultsThe proportion of subsequent EPL was 22.66% (184/812). Significant differences in the proportion of EPL were observed across HCY quartiles (Q1: 10.45%, Q2: 14.80%, Q3: 21.23%, Q4: 43.84%; P < 0.0001). After adjusting for confounders, elevated preconception serum HCY levels were found to be associated with an increased risk of EPL (adjusted OR = 1.27, 95% CI: 1.14-1.42). Participants in Q3 and Q4 had significantly higher odds of EPL than those in Q1, with adjusted ORs of 5.55 (95% CI: 1.01-30.49) for Q3 and 10.79 (95% CI: 1.87-62.37) for Q4. Additionally, the analyses demonstrated a nonlinear relationship between preconception serum HCY levels and EPL risk. In this cohort, when HCY levels were ≥ 10.71 μmol/L, the risk of EPL increased significantly (adjusted OR = 1.27; 95% CI: 1.03-1.58).
conclusionsElevated preconception serum HCY levels were associated with an increased risk of EPL in women with RPL, and the data-derived threshold of 10.71 μmol/L supports preconception risk stratification in this high-risk population.
Indexed as
Identifiers
42455357What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.